Perspective Therapeutics reports 29% response rate in [212Pb]VMT01 melanoma cohort 3.0 mCi trial

Perspective Therapeutics, Inc.

Perspective Therapeutics, Inc.

CATX

0.00
  • Perspective Therapeutics flagged new interim findings from its Phase 1/2a melanoma study of MC1R-targeted alpha therapy [212Pb]VMT01, with results already disclosed ahead of a planned poster presentation at the 2026 ASCO Annual Meeting.
  • The update pointed to additional anti-tumor activity in a heavily pre-treated monotherapy cohort, with most treated patients showing disease control, supporting continued dose evaluation.
  • Safety remained broadly manageable across treated patients, with no treatment-limiting safety signals highlighted in the release.
  • The company also indicated ongoing progress in its other radiopharmaceutical programs, with more clinical updates expected in late 2026, keeping multiple shots on goal in its pipeline.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Perspective Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605211751PRIMZONEFULLFEED9725091) on May 21, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.